- Home
- KALV
as 06-18-2025 3:37pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 642.3M | IPO Year: | N/A |
| Target Price: | $24.83 | AVG Volume (30 days): | 717.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $15.50 | Next Earning Date: | 07-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Jun 6 '25 | Sell | $14.50 | 7,169 | $103,950.50 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 22 '25 | Sell | $11.31 | 1,926 | $21,781.71 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 22 '25 | Sell | $11.31 | 2,146 | $24,271.69 | 113,026 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | May 21 '25 | Sell | $11.88 | 9,999 | $118,743.12 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 21 '25 | Sell | $11.88 | 2,317 | $27,515.53 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 21 '25 | Sell | $11.88 | 2,689 | $31,933.22 | 113,026 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | May 17 '25 | Sell | $11.84 | 3,808 | $45,097.38 | 315,074 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | May 17 '25 | Sell | $11.84 | 2,600 | $30,791.28 | 98,189 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | May 17 '25 | Sell | $11.84 | 2,776 | $32,875.61 | 113,026 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Apr 9 '25 | Buy | $9.42 | 25,000 | $235,500.00 | 5,303,985 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues
Business Wire
3 days ago
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
BioPharma Dive
3 days ago
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
MT Newswires
6 days ago
KalVista Says FDA to Miss PDUFA Goal Date for Sebetralstat Application
Business Wire
6 days ago
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
Business Wire
14 days ago
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
Business Wire
16 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
17 days ago
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.